Economic Evaluation of Mailed Home-Based Human Papillomavirus Self-sampling Kits for Cervical Cancer Screening
JAMA Network Open · 22.03.2023 · 6 (3) · e234052
DOI: 10.1001/jamanetworkopen.2023.4052 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 22.03.2023. Verfasst von Richard T Meenan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Papillomavirus Infections. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Importance Human papillomavirus (HPV) self-sampling addresses barriers to cervical cancer screening, and mailed self-sampling kits have been reported to increase screening uptake. International research suggests mailed kits are cost-effective in certain settings. However, the cost-effectiveness of mailing HPV self-sampling kits for increasing screening uptake has not been evaluated in the US.
Objective
To conduct an economic evaluation of a mailed HPV self-sampling intervention among underscreened women enrolled in an integrated US health care system. Design, Setting, and Participants This economic evaluation involved a cost-effectiveness analysis of results from a randomized clinical trial of 19 851 women aged 30 to 64 years enrolled in a health plan from Kaiser Permanente Washington (KPWA), a US-based integrated health care system. Women were identified through electronic medical records, and eligible participants were enrolled in a health plan for at least 3 years and 5 months, had a primary care clinician, had not received a Papanicolaou test for at least 3 years and 5 months, and had not received a hysterectomy. Enrollment occurred from February 25, 2014, to August 29, 2016, with follow-up through February 25, 2018. The current economic evaluation was conducted between August 2, 2021, and July 30, 2022. Intervention delivery costs were calculated from both the KPWA and Medicare perspectives and were based on either wellness visit or Papanicolaou test–only visit costs.
Intervention
Participants in the control group received usual care, which comprised patient reminders and ad hoc outreach for screening. Participants in the intervention group received usual care plus a mailed HPV self-sampling kit. Main Outcome and Measures The primary economic outcome was the incremental cost-effectiveness ratio (ICER) for increased screening uptake, defined as the incremental difference in cost (intervention group minus control group) divided by the difference in the number of participants completing screening (intervention group minus control group) within 6 months of randomization.
Results
Among 19 851 women (mean [SD] age, 50.1 [9.5] years; 76.7% White), 9960 were randomized to the intervention group, and 9891 were randomized to the control group. Baseline ICERs ranged from $85.84 (95% CI, $85.68-$85.99) using KPWA wellness visits as the cost basis to $146.29 (95% CI, $146.20-$146.38) using Medicare Papanicolaou test–only visits as the cost source. Subgroups of participants aged 50 to 64 years and participants most recently overdue for screening achieved cost-effectiveness at lower levels of willingness to pay for an additional completed screening than other subgroups. Conclusions and Relevance In this economic evaluation, mailing HPV self-sampling kits to women overdue for cervical cancer screening was cost-effective for increased screening uptake relative to usual care. These results support mailing HPV kits as an efficient outreach strategy for increasing screening rates among eligible women in US health care systems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Center for Health Research, Kaiser Permanente Northwest, Portland, Oregon.
- Department of Epidemiology, University of Washington School of Public Health, Seattle.
- Kaiser Permanente Washington Health Research Institute, Seattle.
- Department of Clinical Sciences, The University of Texas Southwestern Medical Center, Dallas.
- Washington Permanente Medical Group, Seattle.
- Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California.
Förderung
- NCI NIH HHS
Zitieren
APA
Meenan, R. T., Troja, C., Buist, D. S. M., Tiro, J. A., Lin, J., Anderson, M. L., Gao, H., Green, B. B., & Winer, R. L. (2023). Economic Evaluation of Mailed Home-Based Human Papillomavirus Self-sampling Kits for Cervical Cancer Screening. JAMA Network Open, 6(3), e234052. https://doi.org/10.1001/jamanetworkopen.2023.4052
Vancouver
Meenan RT, Troja C, Buist DSM, Tiro JA, Lin J, Anderson ML, et al. Economic Evaluation of Mailed Home-Based Human Papillomavirus Self-sampling Kits for Cervical Cancer Screening. JAMA Network Open. 2023;6(3):e234052. doi:10.1001/jamanetworkopen.2023.4052
BibTeX
@article{Meenan2023,
author = {Meenan, Richard T and Troja, Catherine and Buist, Diana S M and Tiro, Jasmin A and Lin, John and Anderson, Melissa L and Gao, Hongyuan and Green, Beverly B and Winer, Rachel L},
title = {Economic Evaluation of Mailed Home-Based Human Papillomavirus Self-sampling Kits for Cervical Cancer Screening},
journal = {JAMA Network Open},
year = {2023},
volume = {6},
number = {3},
pages = {e234052},
doi = {10.1001/jamanetworkopen.2023.4052}
}
EUVIMED